SALES!!!!!!!!!!
GTG is unable to sell its genetic tests !!!!
ASX Half-year ended 31 Dec 2018 - Sales for 2017 = US$97,790
Sales for 2018 = US$18,402
In the Investor Presentation 02 May 2019 there is NO mention of sales !!!! This presentation just mentions very vague words like "distribution channel"
The big carrot of hope being dangled in front of investors is the "US$925 billion" healthcare market in China - the BREVAGenplus test is validated for Caucasian, African American and Hispanic women, but no indication it has been (or is currently being) validated for Asian women.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
3.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $52.08M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| GTG (ASX) Chart |
Day chart unavailable